Related Experiment Video
Updated: Jun 27, 2025
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Fecal microbiota transplantation for irritable bowel syndrome: Current evidence and perspectives
Cong Dai1, Yu-Hong Huang1, Min Jiang2
1Department of Gastroenterology, First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
Abstract:
In this editorial we comment on the article published in the recent issue of the World journal of Gastroenterology. We focus specifically on the mechanisms un-derlying the effects of fecal microbiota transplantation (FMT) for irritable bowel syndrome (IBS), the factors which affect the outcomes of FMT in IBS patients, and challenges. FMT has emerged as a efficacious intervention for clostridium difficile infection and holds promise as a therapeutic modality for IBS. The utilization of FMT in the treatment of IBS has undergone scrutiny in numerous randomized controlled trials, yielding divergent outcomes. The current frontier in this field seeks to elucidate these variations, underscore the existing knowledge gaps that necessitate exploration, and provide a guideline for successful FMT imple-mentation in IBS patients. At the same time, the application of FMT as a treatment for IBS confronts several challenges.
Insights
Fecal microbiota transplantation (FMT) shows promise for irritable bowel syndrome (IBS) treatment, but outcomes vary. Further research is needed to understand FMT mechanisms and optimize its use in IBS patients.
Area of Science:
- Gastroenterology
- Microbiome research
- Clinical trials
Background:
- Fecal microbiota transplantation (FMT) is a proven treatment for Clostridium difficile infection.
- FMT is being investigated as a potential therapy for Irritable Bowel Syndrome (IBS).
- Randomized controlled trials on FMT for IBS have produced inconsistent results.
Discussion:
- This editorial discusses the mechanisms behind FMT's effects on IBS.
- It examines factors influencing FMT outcomes in IBS patients.
- Key challenges in applying FMT for IBS are highlighted.
Key Insights:
- Understanding the variability in FMT response for IBS is crucial.
- Identifying factors that predict successful FMT outcomes is a priority.
- Elucidating the precise mechanisms of FMT in IBS is an ongoing research area.
Outlook:
- Further research is needed to address knowledge gaps in FMT for IBS.
- Guidelines for successful FMT implementation in IBS patients are being developed.
- Overcoming current challenges is essential for advancing FMT as an IBS therapy.
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:30Irritable Bowel Syndrome III: Medical and Nursing Management